Literature DB >> 18031992

Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?

R Walter Heinrichs1, Narmeen Ammari, Stephanie McDermid Vaz, Ashley A Miles.   

Abstract

This study sought to objectify the distinction between schizophrenia and schizoaffective disorder in terms of standard tasks measuring verbal and non-verbal cognitive ability, auditory working memory, verbal declarative memory and visual processing speed. Research participants included 103 outpatients with a diagnosis of schizophrenia, 48 with schizoaffective disorder, and 72 non-patients from the community. Schizophrenia patients were impaired on all cognitive measures relative to schizoaffective patients and non-psychiatric participants. Regression-based prediction models revealed that cognitive measures classified schizophrenia patients accurately (91%), but not patients with schizoaffective disorder (35%). In addition, there was no statistical evidence for the unique predictive validity of any specific cognitive task. Patients with schizophrenia were significantly more symptomatic and had greater community support requirements than those with schizoaffective disorder. However, group differences in cognitive performance are insufficient to separate these syndromes of psychotic illness.

Entities:  

Mesh:

Year:  2007        PMID: 18031992     DOI: 10.1016/j.schres.2007.10.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Cognition in schizophrenia: core psychological and neural mechanisms.

Authors:  Deanna M Barch; Alan Ceaser
Journal:  Trends Cogn Sci       Date:  2011-12-12       Impact factor: 20.229

Review 2.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

3.  Anticipating DSM-V: opportunities and challenges for cognition and psychosis.

Authors:  Deanna M Barch; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2009-11-18       Impact factor: 9.306

4.  Cognitive impairments in psychotic disorders: common mechanisms and measurement.

Authors:  Deanna M Barch; Julia M Sheffield
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

5.  Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.

Authors:  Carmen Simonsen; Kjetil Sundet; Anja Vaskinn; Astrid B Birkenaes; John A Engh; Ann Faerden; Halldóra Jónsdóttir; Petter Andreas Ringen; Stein Opjordsmoen; Ingrid Melle; Svein Friis; Ole A Andreassen
Journal:  Schizophr Bull       Date:  2009-05-14       Impact factor: 9.306

6.  Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different.

Authors:  A Owoso; C S Carter; J M Gold; A W MacDonald; J D Ragland; S M Silverstein; M E Strauss; D M Barch
Journal:  Psychol Med       Date:  2013-03-25       Impact factor: 7.723

7.  Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder.

Authors:  Daniel H Mathalon; Ralph E Hoffman; Todd D Watson; Ryan M Miller; Brian J Roach; Judith M Ford
Journal:  Front Hum Neurosci       Date:  2010-01-29       Impact factor: 3.169

8.  Bridging the gap between schizophrenia and psychotic mood disorders: Relating neurocognitive deficits to psychopathology.

Authors:  Matthew J Smith; Deanna M Barch; John G Csernansky
Journal:  Schizophr Res       Date:  2008-09-10       Impact factor: 4.939

Review 9.  Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences.

Authors:  Deanna M Barch
Journal:  Curr Psychiatry Rep       Date:  2009-08       Impact factor: 5.285

10.  Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients.

Authors:  Rosa Ayesa-Arriola; José Manuel Rodríguez-Sánchez; Esther Setién Suero; Lauren E Reeves; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-14       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.